See What HealthDay Can Do For You
Contact Us

Production of Two Excedrin Painkillers Halted

Inconsistencies found in ingredients for Excedrin Extra Strength and Excedrin Migraine

pills

WEDNESDAY, Jan. 22, 2020 (HealthDay News) -- Production and distribution of Excedrin Extra Strength and Excedrin Migraine products have been temporarily stopped, maker GlaxoSmithKline said Tuesday.

"Through routine quality control and assurance measures, we discovered inconsistencies in how we transfer and weigh ingredients for Excedrin Extra Strength Caplets and Geltabs, and Excedrin Migraine Caplets and Geltabs," the company said in a statement to CNN.

"We are working hard to resolve the issue as quickly as possible, but at this point in time cannot confirm a definite date as to when supply will resume," the company said.

"Other Excedrin products are available along with other pain-relieving drugs, but dosages may differ. Consumers should consult their pharmacist for the most suitable alternative product," GlaxoSmithKline advised.

CNN Article

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.